<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767468</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 0717</org_study_id>
    <secondary_id>P30CA016086</secondary_id>
    <secondary_id>CDR0000615311</secondary_id>
    <secondary_id>BAYER-UNC-LCCC-0717</secondary_id>
    <nct_id>NCT00767468</nct_id>
  </id_info>
  <brief_title>Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis</brief_title>
  <official_title>A Phase IB Study of Sorafenib for Patient With Locally Advanced or Metastatic Hepatocellular Carcinoma and Child's B Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in&#xD;
      treating patients with locally advanced or metastatic liver cancer and cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the pharmacokinetic parameters of sorafenib tosylate in patients with&#xD;
           locally advanced or metastatic hepatocellular carcinoma and Child-Pugh B cirrhosis.&#xD;
&#xD;
        -  To correlate the pharmacokinetic parameters of sorfenib tosylate with hepatic retention&#xD;
           and clearance of technetium Tc 99m mebrofenin (MEB) and technetium Tc 99m sestamibi&#xD;
           (MIBI).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To establish a tolerable dose of sorafenib tosylate based on degree of liver dysfunction&#xD;
           (bilirubin ≤ 3 times upper limit of normal [ULN] or bilirubin &gt; 3 times but ≤ 6 times&#xD;
           ULN).&#xD;
&#xD;
        -  To correlate the pharmacokinetics MEB and MIBI with the dose-limiting toxicity of&#xD;
           sorafenib tosylate.&#xD;
&#xD;
        -  To explore whether increase in bilirubin consists primarily of conjugated or&#xD;
           unconjugated bilirubin in response to sorafenib tosylate.&#xD;
&#xD;
        -  To explore whether there is a correlation between increased bilirubin and decreased&#xD;
           clearance of MEB and/or MIBI.&#xD;
&#xD;
        -  To explore whether there is a correlation between survival and MRI characteristics&#xD;
           associated with high tumor VEGF levels.&#xD;
&#xD;
        -  To assess VEGF levels directly in available biopsy samples using IHC.&#xD;
&#xD;
        -  To determine expression levels of hepatic transport proteins (i.e., OATPs, Pgp, or MRPs)&#xD;
           that may correlate with clearance of sorafenib tosylate.&#xD;
&#xD;
        -  To explore whether there is a correlation between survival and activation of the&#xD;
           RAF/MEK/ERK pathway at baseline.&#xD;
&#xD;
        -  To estimate median overall survival.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to degree of hepatic&#xD;
      dysfunction (moderate [bilirubin ≤ 3 times upper limit of normal (ULN)] vs severe [bilirubin&#xD;
      &gt; 3 times but ≤ 6 times ULN]).&#xD;
&#xD;
      Patients receive oral sorafenib tosylate twice daily on days 1-28. Courses repeat every 28&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo hepatic scintigraphy with technetium Tc 99m mebrofinin (MEB) and technetium&#xD;
      Tc 99m sestamibi (MIBI) at baseline. Blood and urine samples are collected periodically for&#xD;
      pharmacokinetic studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 3-4 weeks and then every 3 months&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding unavailable&#xD;
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between hepatic retention and clearance of technetium Tc 99m mebrofenin (MEB) and technetium Tc 99m sestamibi (MIBI) and clearance (and other pharmacokinetic parameters) of sorafenib tosylate</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerable dose of sorafenib tosylate</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the pharmacokinetics of MEB and MIBI and the dose-limiting toxicity of sorafenib tosylate</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjugated or unconjugated bilirubin increase in response to sorafenib tosylate</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between increased bilirubin and decreased clearance of MEB and/or MIBI</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between survival and MRI characteristics associated with high tumor VEGF levels</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between clearance of sorafenib tosylate and expression levels of hepatic transport proteins</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between survival and activation of the RAF/MEK/ERK pathway at baseline</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Bilirubin Normal to 3x Upper Limit of Normal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilirubin &gt;3x to 6x Upper Limit of Normal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Sorafenib 400mg BID until disease progression or patient withdrawal.</description>
    <arm_group_label>Bilirubin &gt;3x to 6x Upper Limit of Normal</arm_group_label>
    <arm_group_label>Bilirubin Normal to 3x Upper Limit of Normal</arm_group_label>
    <other_name>Sorafenib</other_name>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of hepatocellular carcinoma (HCC) according to tissue histology* NOTE:&#xD;
             *Recurrence of previously resected HCC does not require tissue confirmation if there&#xD;
             is clear radiographic recurrence, in the opinion of the investigator&#xD;
&#xD;
          -  Locally advanced or metastatic disease OR not eligible for surgical resection or&#xD;
             immediate liver transplantation&#xD;
&#xD;
          -  Child-Pugh class B cirrhosis&#xD;
&#xD;
               -  Moderate hepatic dysfunction (bilirubin ≤ 3 times upper limit of normal [ULN]) OR&#xD;
                  severe hepatic dysfunction (bilirubin &gt; 3 times but ≤ 6 times ULN)&#xD;
&#xD;
          -  No known brain metastasis unless the metastasis has been stable for &gt; 3 months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
          -  ANC &gt; 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 45,000/mm^3&#xD;
&#xD;
          -  ALT and AST &lt; 7 times ULN&#xD;
&#xD;
          -  INR &lt; 2.0&#xD;
&#xD;
          -  Creatinine &lt; 1.7 times ULN OR creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 2 weeks after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No history of uncontrolled seizures, CNS disorders, or psychiatric disability that, in&#xD;
             the opinion of the investigator, is clinically significant, precludes giving informed&#xD;
             consent, or interferes with compliance of oral drug intake&#xD;
&#xD;
          -  No other concurrent active malignancy&#xD;
&#xD;
          -  No active clinically serious infection &gt; CTCAE grade 2&#xD;
&#xD;
          -  No known hypersensitivity to sorafenib tosylate or to any of the excipients&#xD;
&#xD;
          -  No known or suspected allergy to sorafenib tosylate or to any agent given in the&#xD;
             course of this study&#xD;
&#xD;
          -  No NYHA class III or IV congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No new onset angina (i.e., within the past 3 months)&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No cardiac ventricular arrhythmias requiring anti-arrhythmic therapy&#xD;
&#xD;
          -  No uncontrolled hypertension, defined as systolic blood pressure (BP) &gt; 150 mm Hg or&#xD;
             diastolic BP &gt; 90 mm Hg, despite optimal medical management&#xD;
&#xD;
          -  No thrombolic or embolic events (e.g., cerebrovascular accident, including transient&#xD;
             ischemic attacks) within the past 6 months&#xD;
&#xD;
          -  No pulmonary hemorrhage/bleeding event &gt; CTCAE grade 2 within the past 4 weeks&#xD;
&#xD;
          -  No other hemorrhage/bleeding event &gt; CTCAE grade 3 within the past 4 weeks&#xD;
&#xD;
          -  No variceal bleeding within the past 90 days&#xD;
&#xD;
          -  No known grade 2 or 3 esophageal varices&#xD;
&#xD;
          -  No evidence or history of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  No significant traumatic injury within the past 4 weeks&#xD;
&#xD;
          -  No serious non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No other serious uncontrolled medical condition (e.g., uncontrolled ascites or&#xD;
             encephalopathy) that, in the opinion of the investigator, may compromise study&#xD;
             participation&#xD;
&#xD;
          -  No condition that would impair the patient's ability to swallow whole pills&#xD;
&#xD;
          -  No malabsorption problem&#xD;
&#xD;
          -  No active drug or alcohol abuse&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No more than one prior therapy including, but not limited to, any of the following:&#xD;
&#xD;
               -  Systemic chemotherapy&#xD;
&#xD;
               -  Hepatic artery infusion of chemotherapy&#xD;
&#xD;
               -  Chemoembolization&#xD;
&#xD;
               -  Radioembolization&#xD;
&#xD;
               -  Ablation&#xD;
&#xD;
          -  At least 4 weeks since prior embolization, resection, or ablation&#xD;
&#xD;
          -  No prior RAF/MEK/ERK-targeting therapy or VEGF-targeting therapy&#xD;
&#xD;
          -  More than 4 weeks since prior participation in an investigational drug study&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery or open biopsy&#xD;
&#xD;
          -  No concurrent chronic anticoagulation other than 1 mg of warfarin per day for central&#xD;
             venous catheter patency&#xD;
&#xD;
          -  No concurrent St. John's wort or rifampin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bert H. O'Neil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>October 4, 2008</study_first_submitted>
  <study_first_submitted_qc>October 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>May 22, 2012</last_update_submitted>
  <last_update_submitted_qc>May 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

